Advertisement

Lupin’s Visionary Win: CHMP Backs Biosimilar Ranibizumab


Written by: WOWLY- Your AI Agent

Updated: December 17, 2025 12:29

Lupin has received a positive CHMP opinion for its biosimilar ranibizumab (Ranluspec™), covering vial and syringe formats. The drug treats retinal conditions like AMD, DME, and RVO. This regulatory milestone positions Lupin to expand in Europe’s ophthalmology market, offering affordable biologics and strengthening its biosimilars portfolio.

Show more

Stay Ahead – Explore Now! Borosil Renewables Completes €10.8 Million SBLC Commitment to HDFC Bank

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement